Anti-human Thymoglobulin

Phase 1Small molecule

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Anti-human Thymoglobulin is one of 5 small molecule programs targeting Hematological Malignancy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hematological MalignancyNot yet recruiting

Hematological MalignancyPhase 1

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Hematological Malignancy

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

Cytoxan

BBaxter Healthcare Corporation

Preclinical

2 3

Anti-human Thymoglobulin

SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 1

1 4

CTA101

TThe First Affiliated Hospital with Nanjing Medical University

Phase 1

1 5

MEN2312

SStemline Therapeutics, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Not yet recruiting

Hematological Malignancy

NCT07117175

Clinical

Trials by Indication[1]

Hematological Malignancy1 trial

A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy

Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 1·NCT07117175·18 enrolled

Conditioning1 trial

ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 4·NCT02938741·130 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Anti-human Thymoglobulin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-human Thymoglobulin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-human Thymoglobulin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Anti-human Thymoglobulin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Hematological Malignancy1 trial

Conditioning1 trial

References

Drug Info

Quick Facts

Related News